Despite being recognised for over two millennia and having an increasing incidence in many countries, the management of childhood empyema remains controversial. This review examines the recent literature on its causes and investigation then focuses on its treatment. Following a trial of appropriate intravenous antibiotics, the evidence would currently support the use of chest drain insertion with urokinase instillation as fi rst line treatment with video-assisted thoracoscopic surgery to be used for failure of medical management. A treatment algorithm is proposed to guide clinical practice.
INTRODUCTION
Empyema has been recognised for over two millennia. Hippocrates wrote in 400 BC, 'when the empyema is treated either by cautery or incision, if pure and white pus fl ow from the wound, the patient will recover, but if mixed with blood, slimy and fetid, they die'. 1 Yet despite centuries of recognition and recent increasing incidence, its management remains controversial.
There are many aspects of childhood empyema that signifi cantly differ from its adult counterpart including causative pathogens, patient characteristics and outcome. It is, therefore, inappropriate to extrapolate adult therapeutic data directly to children. There remains a paucity of evidence to inform best management in childhood as highlighted in the British Thoracic Society 2005 guideline on the management of paediatric pleural infection. 2 Of the 57 recommendations, 45 were based on case reports or expert opinion only. Since the guideline's publication there have been a number of studies published in this area, particularly addressing the question of optimal management.
In this article we review the up-to-date evidence on the causes and investigation of empyema in children then focus on its management. A full discussion of all aspects of paediatric empyema is outside the scope of this update and we would encourage the reader to also review the British Thoracic Society guideline, which provides a comprehensive overview. 2 
NATURAL HISTORY AND TERMINOLOGY
Pleural empyema, from Greek 'pyon' meaning pus, develops most commonly after infection of a parapneumonic effusion (PPE) secondary to an adjacent bacterial pneumonia. The transition from PPE to empyema represents a continuum from clear fl uid with low white cell numbers to overt pus. The development of a robust, widely acknowledged staging system for this continuum using radiological and/or biological parameters remains a signifi cant challenge. 3 
RISING INCIDENCE
Recent evidence would suggest that the incidence of empyema complicating bacterial pneumonia is increasing in the UK, USA and Europe, particularly over the last decade. [4] [5] [6] [7] In Scotland childhood empyema admissions rose from an average of 6.5 per million per year between 1981 and 1998 to 66 per million in 2005 with no concomitant increase in pneumonia admissions (fi gure 1). 8 The reasons for this dramatic increase are not known but possibilities include changing bacterial resistance and virulence, alteration of climate, introduction of the pneumococcal vaccination and adjustments to primary care antibiotic prescribing practices and referral patterns. 9 
MICROBIOLOGY AND THE IMPACT OF PNEUMOCOCCAL VACCINATION
Conventional culture techniques fail to identify a causative organism in over 70% of empyema cases, most likely due to previous antibiotic therapy. [10] [11] [12] However, the advent of molecular techniques such as PCR, have enabled identifi cation of a pathogen in the majority of 'culture-negative' cases. 10 In the developed world, such studies have reiterated Streptococcus pneumoniae as the principal pathogen in empyema, with its identifi cation in over 80% of culture-negative cases in some reports. 13 Staphylococcus aureus represents the next most commonly identifi ed pathogen with other bacteria less frequently implicated (box 1). It is increasingly recognised that most cases of empyema are caused by a limited number of pneumococcal serotypes. Serotype 1 has been consistently identifi ed as the principal pathogen, although recent data suggest the emergence of other serotypes, particularly types 3 and 19A. 12 14-17 The identifi cation of specifi c culpable serotypes has been widely studied in the context of the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7). PCV7 has been included in the UK childhood vaccination schedule since 2006 following its introduction in the USA in 2000 and has been associated with a signifi cant reduction in paediatric invasive pneumococcal disease (IPD). 18 However, PCV7 does not provide coverage for several of the principal serotypes identifi ed in empyema, including serotype 1. This has been highlighted in a number of studies, Jaffe et al reporting 91% of pneumococci identifi ed in empyema belonging to a non-PCV7 serotype in a recent Australian study. 14 17 19 This lack of coverage has led to an examination of PCV7's potential role in the increasing incidence of empyema. Following its introduction, Hendrickson et al reported a fi vefold increase in empyema in children in California, and De Wals et al found that despite a 13.2% decrease in pneumonia admission rates there was no observed reduction in empyema rate. 20 21 Compelling though this may appear, a causal relationship has not been proven and some evidence suggests that empyema rates increased signifi cantly in certain parts of the world before the introduction of PCV7. 6 22 The new 13-valent pneumococcal conjugate vaccine (PCV13) due for release in the UK soon, covers serotypes 1, 3 and 19A. Recent data from the Health Protection Agency showed that in 2007/2008 there were 470 cases of IPD in under 5-year olds, 24% of the serotypes were covered by PCV7 but 74% would have been covered by PCV13. It will be interesting to see how this will impact on the incidence of empyema. 23 
INVESTIGATION
The clinical features of PPE are frequently subtle and can closely resemble those of an uncomplicated pneumonia. It is therefore paramount that the possibility of a developing PPE is considered in all children presenting with pneumonia. The judicious use of appropriate investigations can clarify what is often a diffi cult clinical diagnosis (box 2).
IMAGING

Chest radiograph
A chest radiograph (CxR) is frequently the fi rst investigation to suggest the presence of PPE. Early signs include blunting of the costophrenic angle and a lateral rim of fl uid around the lung. In addition, a CxR may reveal fi ndings that help establish an underlying cause, for example, hilar lymphadenopathy or evidence of a lung abscess. With large effusions there may be a complete 'white out' of the lung fi eld making it impossible to differentiate between pleural fl uid and consolidated lung. 24 Lateral decubitus radiographs can help distinguish fl uid from pleural thickening but are not routinely recommended given the ready availability of ultrasound. 2 A CxR is often used to assess treatment response particularly following chest drain insertion and can demonstrate resolution and tube-related complications such as pneumothorax and malposition. Ongoing CxR changes such as pleural thickening and underlying consolidation are frequently observed following treatment and, in isolation, do not constitute failed therapy. Radiological abnormalities (particularly pleural thickening) may persist for 3-6 months following successful treatment. 25 
Chest ultrasound scan
Chest ultrasound scan (USS) remains the central investigation in the management of empyema. Its strengths are that it is non-invasive, portable, cheap and does not involve ionising radiation. It provides a dynamic assessment of the chest which can differentiate pleural fl uid from consolidated lung, demonstrate fi brinous strands within the fl uid, assess loculation of fl uid and, perhaps most importantly, estimate the size of effusion and guide chest drain placement (fi gure 2). 26 However, USS cannot accurately differentiate between an exudate and pus in the pleural cavity. Approximately a third of empyemas were anechoic in one large study and studies evaluating the ability of USS to predict outcome and treatment response have been confl icting. 26 27 Chest CT Chest CT scans enable identifi cation of a number of recognised features of PPE including increased density of subcostal fat and pleural enhancement and thickening. However, in childhood, CT does not appear able to reliably differentiate empyema from a simple effusion, radiation doses are significant (approximately 115 times that of a CxR) and the child may require sedation or a general anaesthetic. 26 28 29 A recent study found that CT detected more parenchymal abnormalities than CxR but did not alter management or predict clinical outcome. The study concluded that there is no role for the routine use of CT scanning in childhood PPE although the study may have been underpowered to detect small differences. 30 It is important that chest CT is considered in selected cases where there is concern that infection is not the underlying cause, particularly those with late presenting empyema, blood stained pleural fl uid or in a case that is not clinically improving with appropriate treatment. 31 
BLOOD TESTS
An initial white cell count and C reactive protein should be performed to provide supportive evidence for an infective aetiology of PPE. Serial measurements can be helpful in monitoring progress. Blood cultures should be taken, despite the low isolation rate in PPE (10-22%) as they may be positive when pleural fl uid culture proves sterile. 5 32 PCR analysis of blood for pneumococcus does not appear to add diagnostically to blood culture results. 33 
PNEUMOCOCCAL URINARY ANTIGEN TESTING
A recently introduced immunochromatographic membrane test (BINAX NOW) for rapid detection of pneumococcal C polysaccharide antigens in urine has gained wide acceptance in adult practice. 34 However, in childhood, a false positive result can occur as a result of recent pneumococcal vaccination or ongoing nasopharyngeal carriage. A positive result should therefore be interpreted with caution, although a number of studies have demonstrated that a negative urine antigen test practically rules out pneumococcal infection. 35 36 
SPUTUM
Any available sputum should be sent for culture, although the low quality of specimens often obtained from children can limit the usefulness of this analysis. The possibility of using hypertonic saline to induce sputum from children as young as 6 months has been outlined in a recent Finnish study. Good quality specimens were obtained in 57% of children with community acquired pneumonia, with bacteria identifi ed (using a combination of culture and PCR) in 79% of these specimens. 37 PCR analysis of respiratory specimens has become more widely available, enabling rapid identifi cation of potential pathogens. Once again, results are dependent on sputum quality and, in respect of pneumococcus, PCR is not able to distinguish colonisation from infection of the respiratory tract so results should be interpreted with caution. 36 However, PCR is likely to become increasingly used for pathogen identifi cation as experience and techniques improve.
PLEURAL FLUID ANALYSIS
As discussed below, routine diagnostic thoracocentesis is not recommended unless there is doubt regarding an infective cause. Although frequently sterile due to prior administration of antibiotics, any pleural fl uid that is available should undergo microbiological analysis including gram stain, culture and antibiotic sensitivity testing. 2 Fluid should also be sent for cytological analysis as malignant cells may be observed and a lymphocytosis rather than neutrophilia may indicate tuberculosis or malignancy. Both pneumococcal antigen testing and pneumococcal PCR can be performed on pleural fl uid and have high sensitivity and specifi city, PCR can even suggest penicillin susceptibility, and should be considered if available. 38 39 
MANAGEMENT
The goals of treatment are sterilisation of the pleural cavity and drainage of pleural fl uid, in order to allow re-expansion of the lung and restoration of normal pleural fl uid circulation. 24 This should be achieved in the shortest time possible, while exposing the child to the least trauma, radiation and risk. Morbidity can be signifi cant in certain cases particularly those with associated necrotising pneumonia or co-morbidities. 40 However, it is important to appreciate that empyema in childhood is associated with a low mortality (<0.5% in a large recent series 41 ) with the majority of children making a complete recovery eventually, irrespective of what treatment they receive, as compared to adult empyema which has a reported mortality approaching 20%. 42 43 There remains debate as to how best to achieve these goals. The vast majority of studies to date have been retrospective comparisons of interventions and there have been few randomised controlled trials (RCTs) published. This has led to treatment being determined by local experience and availability of different treatment options. 
MEDICAL MANAGEMENT Antibiotics alone
There is undoubtedly a role for antibiotic treatment alone in those children without respiratory compromise. Following the introduction of appropriate antibiotics, the decision to proceed to drainage should take into consideration a number of factors including: clinical and fever response to antibiotic therapy at 48-72 h, evidence of enlarging effusion on repeat USS at 48-72 h, response of acute phase reactants. Development of respiratory compromise is an indication for drainage. 24 Decisions on empirical antibiotic treatment should be based on local pneumonia treatment guidelines and take into consideration whether the infection was community or hospitalacquired, local antibiotic resistance patterns and whether the child has any underlying medical problems. Given recent microbiological evidence it is imperative that initial antibiotics provide good S pneumoniae cover pending culture results. If there is radiological evidence of pneumatocoeles adequate staphylococcal cover is required and anaerobic cover should be added if the child is at risk of aspiration. A second or third generation cephalosporin, such as cefuroxime or co-amoxiclav are often used empirically although, particularly in the USA, clindamycin is used as an additional fi rst line agent both due to low S pneumoniae resistance and as cover for the increasing prevalence of methicillin-resistant S aureus. 44 
Thoracocentesis
The role of thoracocentesis in the management of childhood PPE remains unclear. The sample obtained can be analysed for a number of biochemical 'markers' (eg, pH and lactate dehydrogenase) and sent for cytological and microbiological assessment. In adults, such information has proved extremely helpful in guiding management and its place in the diagnostic pathway is well-established. 34 However, thoracocentesis in children is technically challenging, requiring co-operation and sedation, and there remains little data to support the prognostic value of biochemical analyses. Furthermore, thoracocentesis has been shown to result in a signifi cantly higher re-intervention rate when compared to insertion of a pigtail catheter as a primary procedure. 45 Therefore, it would currently appear that thoracocentesis should be reserved for cases where non-infective causes of PPE are being considered. Further studies are required to evaluate potential correlations between pleural fl uid analysis, management options and outcome.
Chest drain insertion alone
While studies have shown that chest drain insertion alone can be effective, the length of stay (LOS) in hospital is prolonged compared to studies using other treatment options. A metaanalysis of 67 studies, found the average LOS for chest drain alone was 20 days compared to 10.7 days for chest drain with the instillation of fi brinolytic agents. 43 Furthermore, this study identifi ed a signifi cantly higher failure rate for chest drain insertion alone compared to chest drain and fi brinolysis (23.6% vs 9.4%). The current evidence would favour instillation of fi brinolytics if chest drain insertion is required.
Chest drain insertion with instillation of a fi brinolytic agent
The aim of an instilled fi brinolytic is to break down fi brin strands and clear lymphatic pores to improve drainage and re-establish pleural circulation. It also ensures chest drain patency by clearing the fenestrations, allowing effective use of smaller catheters.
Numerous case series have been published to date. These have used a variety of fi brinolytics, dosage schedules and treatment protocols. There has also been great diversity in the stage at which treatment is commenced and a number of studies have only used fi brinolysis when chest drainage alone has failed. Not surprisingly, outcomes such as failure rate and LOS are varied. The principle side effects reported have been discomfort during administration and transient blood staining of the drainage fl uid. 2 There have now been fi ve RCTs published studying the use of intrapleural fi brinolytic therapy for childhood empyema (table 1) .
Robust outcome measures for such studies are inherently diffi cult to defi ne. Length of hospital stay is primarily used despite the possibility of variation in discharge criteria and the potential impact of other factors such as frequency of clinical review.
Two studies have compared intrapleural fi brinolytics against normal saline. Thomson et al randomised 58 children who required chest drain insertion to receive six doses of twice daily intrapleural urokinase or normal saline. 46 Treatment with urokinase resulted in a signifi cantly shorter hospital stay (7.4 days vs 9.5 days). Treatment failure, defi ned as need for pleural decortication, occurred in fi ve children (two in the urokinase group). Singh et al compared daily intrapleural streptokinase against saline in 40 children and found no difference in clinical or sonographic outcomes, although group.bmj.com on April 21, 2011 -Published by adc.bmj.com Downloaded from streptokinase prevented pleural thickening in those patients with a multi-loculated empyema. No treatment failures were described. 47 The effi cacy of intrapleural urokinase has subsequently been confi rmed in a further randomised trial and, furthermore, urokinase lacks the potential of streptokinase to cause serious allergic reactions. 48 Therefore, current evidence favours the use of urokinase although tissue plasminogen activator (TPA) has also been shown to be effective and has the advantage of only requiring once daily dosing. 49 
Regimen for intrapleural urokinase
The most widely used dosage regimen is that employed in the study by Thomson et al. 46 40 000 units of urokinase in 40 ml of normal saline, or 10 000 units in 10 ml of normal saline for those under 1 year of age, is given twice daily for 3 days. Intrapleural bupivacaine (0.5-1.0 ml/kg of 0.25% solution) can be administered with the urokinase if the child fi nds it uncomfortable. 2 After instillation the chest drain is clamped for 4 h and the child is encouraged to mobilise. The drain is then left on a suction pressure of −20 cm H 2 O until the next dose.
Size of chest drain
While drain size has not been the subject of a randomised trial there is some evidence to suggest a potential advantage for smaller catheters. Pierrepoint et al retrospectively reviewed their experience of empyema management over a 3-year period and found that pigtail catheters signifi cantly reduced the time a drain was in situ (4.9 days vs 11.5 days), time until the patient became afebrile (4.1 days vs 10.7 days) and time from procedure to discharge (5.6 days vs 15.3 days). 50 Thomson et al identifi ed a signifi cantly shorter hospital stay for those treated with small percutaneous catheters compared to large bore catheters (7.2 days vs 9.4 days). 46 
SURGICAL MANAGEMENT
The role of surgery in the management of childhood empyema is controversial. [51] [52] [53] Previously reserved for cases of failed medical therapy, the advent of less invasive techniques, such as video-assisted thoracoscopic surgery (VATS), has led to an increasing interest in surgery's potential role in primary treatment.
Thoracotomy
Open thoracotomy involves a large posterolateral incision providing good access to enable removal of the thickened pleural rind and irrigation of the pleural cavity. Potential drawbacks include a large scar and the risk of wound infection, persistent air leaks and bleeding. Mini thoracotomy involves a similar procedure through a small incision. The only prospective randomised study of primary thoracotomy versus chest drain insertion reported a signifi cantly shorter LOS in the thoracotomy group but did not employ fi brinolytic therapy in its chest drain arm. 54 Similarly, a retrospective study of 48 patients demonstrated a signifi cantly reduced LOS in children treated with primary thoracotomy compared to chest drain alone, although a subgroup managed with chest drain and fi brinolysis had a LOS comparable to thoracotomy. 11
Video-assisted thoracoscopic surgery
VATS is performed through two or three small incisions made in the chest; one is used for the camera while the others accommodate grasping instruments. VATS enables accurate magnifi ed inspection of the whole pleural cavity and direct vision for all surgical manoeuvres. It limits morbidity to muscles and nerves and reduces the cosmetic scarring associated with large incisions. Numerous units have reported their results with VATS, concluding that it is a safe and effective treatment for empyema. However, its exact place in the management of empyema remains contentious.
A number of retrospective analyses have compared VATS to open thoracotomy for rescue treatment demonstrating less postoperative pain, a better cosmetic result and in some cases a shorter LOS. 55 However, there are no randomised trials comparing primary VATS and open thoracotomy.
Perhaps the area of greatest current debate is the role of VATS versus chest drainage and fi brinolysis in the primary management of empyema. Despite a large number of studies comparing primary VATS to chest drainage, the majority do not include treatment with fi brinolytics and are retrospective with the inherent problems common to such studies. 56 Avansino et al undertook a systematic review of all studies published between 1981 and 2004 addressing treatment options, comparing operative to non-operative treatment (67 studies, n=3781). They found that avoidance of surgery was at the expense of a longer LOS, increased duration of chest drain insertion and increased mortality (0% vs 3.3%). However, in a subgroup of studies where fi brinolytics were instilled, there was equivalence of chest drainage with operative management. 43 Two prospective randomised trials have compared primary VATS to chest drain with intrapleural fi brinolytic in children (table 1) . Sonnappa et al compared primary chest drain with fi brinolysis (urokinase) to VATS in 60 children. They found no difference between treatment groups in LOS after intervention (median 6 days for both), treatment failure rate or radiological outcome at 6 months. However, VATS cost signifi cantly more (US$11 379 vs US$9127). 48 In a similar study, St Peter et al compared once daily TPA via chest drain to VATS in 30 children. Their results were strikingly consistent with the Sonnappa study, fi nding no differences between treatment groups in LOS, days of fever, doses of analgesia and days of oxygen therapy. Once again VATS cost signifi cantly more (US$11 700 vs US$7600). 49 It appears that chest drain with fi brinolysis has signifi cant economic advantages over VATS. However, some caveats remain. Subjects in both the randomised studies had been symptomatic for some time (mean 9.8 and 10 days, respectively). This raises the possibility that one treatment modality could be superior to the other in earlier stages of disease such as that presenting to secondary care. Also, the success of VATS appears highly dependent on operator skill and it is not possible to generalise study results to all units. 57 On balance current evidence suggests that chest drain with fi brinolysis is the preferred primary therapy in empyema and that VATS procedure should be reserved for failure of medical management.
Length of antibiotic therapy
Intravenous antibiotic therapy is usually continued until there is defi nite evidence of clinical improvement and resolving fever. While there is no evidence to guide the duration of subsequent treatment, oral antibiotics, such as co-amoxiclav, are generally continued for 2-4 weeks following discharge. 2 Figure 3 represents a proposed algorithm for the treatment of children with PPE or empyema.
THE FUTURE
The diagnosis and appropriate management of PPE and empyema represent a signifi cant challenge to all those involved with acute paediatric care. This is particularly pertinent in the light of recent evidence, which suggests a rapidly rising incidence, although the impact of new multivalent pneumococcal vaccines is awaited. Recent well-designed studies have gone some way to establishing optimal investigation and treatment protocols although many questions remain unanswered.
The process that leads from PPE to empyema is undoubtedly a highly dynamic one. In order for their results to translate directly into clinical practice, future therapeutic studies will need to characterise subjects precisely with appropriate stratifi cation according to clinical, radiological and biological parameters. Only then will it be clear which are the best treatment choices for individual patients. 
